Author

Amali S. Fernando

QIMR Berghofer Medical Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alex William HewittiD· 1 shared Anthony L. CookiD· 1 shared Anthony Robert WhiteiD· 1 shared Destiny Aranovitch· 1 shared Elina Casoli· 1 shared Eske M. DerksiD· 1 shared Juliana C.S. ChavesiD· 1 shared Lotta E. OikariiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alex William HewittORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Computational drug repurposing identifies N-acetylglucosamine as a potential therapeutic compound for CLN3 Batten disease

Elina Casoli, Amali S. Fernando, Juliana C.S. Chaves, Rebecca L. Johnston, Destiny Aranovitch, Sueanne Chear, Anthony L. Cook, Alex William Hewitt, Eske M. Derks, Anthony Robert White, Zachary F. Gerring, Lotta E. Oikari

The paper uses computational drug repurposing to identify N-acetylglucosamine as a potential therapy for CLN3 Batten disease, showing it reduces lipofuscin burden in cell models.

bioRxiv · May 15, 2026 · PreprintNeuroscience